Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Sep;66(3):542–546. doi: 10.1038/bjc.1992.310

CMV chemotherapy for advanced transitional cell carcinoma.

G M Jeffery 1, G M Mead 1
PMCID: PMC1977932  PMID: 1520591

Abstract

Between May 1986 and September 1990 a total of 43 patients with metastatic transitional cell carcinoma (TCC) of the urinary tract have been treated at our institution with combination chemotherapy (CMV) consisting of cisplatin 100 mg m-2 i.v. day 2; methotrexate 30 mg m-2 i.v. days 1.8; and vinblastine 4 mg m-2 i.v. days 1.8. Chemotherapy was recycled on day 22 and continued for a maximum of six cycles in responding patients. Of 33 patients with measurable disease 8 (24%) achieved a complete remission (CR). The median survival for patients achieving a CR was 13 months (range 5-29+) whilst the median survival for all 43 patients was 7 months (range 1-29+). Only three patients are still alive--two are disease free. More effective and/or less toxic chemotherapy regimens are needed for the treatment of patients with metastatic TCC.

Full text

PDF
542

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Babaian R. J., Johnson D. E., Llamas L., Ayala A. G. Metastases from transitional cell carcinoma of urinary bladder. Urology. 1980 Aug;16(2):142–144. doi: 10.1016/0090-4295(80)90067-9. [DOI] [PubMed] [Google Scholar]
  2. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  3. Harker W. G., Meyers F. J., Freiha F. S., Palmer J. M., Shortliffe L. D., Hannigan J. F., McWhirter K. M., Torti F. M. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol. 1985 Nov;3(11):1463–1470. doi: 10.1200/JCO.1985.3.11.1463. [DOI] [PubMed] [Google Scholar]
  4. Hillcoat B. L., Raghavan D., Matthews J., Kefford R., Yuen K., Woods R., Olver I., Bishop J., Pearson B., Coorey G. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol. 1989 Jun;7(6):706–709. doi: 10.1200/JCO.1989.7.6.706. [DOI] [PubMed] [Google Scholar]
  5. Logothetis C. J., Dexeus F. H., Finn L., Sella A., Amato R. J., Ayala A. G., Kilbourn R. G. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990 Jun;8(6):1050–1055. doi: 10.1200/JCO.1990.8.6.1050. [DOI] [PubMed] [Google Scholar]
  6. Logothetis C. J., Dexeus F. H., Sella A., Amato R. J., Kilbourn R. G., Finn L., Gutterman J. U. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst. 1990 Apr 18;82(8):667–672. doi: 10.1093/jnci/82.8.667. [DOI] [PubMed] [Google Scholar]
  7. Potter M. E., Hatch K. D., Potter M. Y., Shingleton H. M., Baker V. V. Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer. 1989 Apr 1;63(7):1283–1286. doi: 10.1002/1097-0142(19890401)63:7<1283::aid-cncr2820630709>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  8. Scher H. I. Should single agents be standard therapy for urothelial tract tumors? J Clin Oncol. 1989 Jun;7(6):694–697. doi: 10.1200/JCO.1989.7.6.694. [DOI] [PubMed] [Google Scholar]
  9. Soloway M. S., Einstein A., Corder M. P., Bonney W., Prout G. R., Jr, Coombs J. A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study. Cancer. 1983 Sep 1;52(5):767–772. doi: 10.1002/1097-0142(19830901)52:5<767::aid-cncr2820520502>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  10. Sternberg C. N., Yagoda A., Scher H. I., Watson R. C., Ahmed T., Weiselberg L. R., Geller N., Hollander P. S., Herr H. W., Sogani P. C. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985 Mar;133(3):403–407. doi: 10.1016/s0022-5347(17)48996-8. [DOI] [PubMed] [Google Scholar]
  11. Sternberg C. N., Yagoda A., Scher H. I., Watson R. C., Geller N., Herr H. W., Morse M. J., Sogani P. C., Vaughan E. D., Bander N. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989 Dec 15;64(12):2448–2458. doi: 10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  12. Sternberg C. N., Yagoda A., Scher H. I., Watson R. C., Herr H. W., Morse M. J., Sogani P. C., Vaughan E. D., Jr, Bander N., Weiselberg L. R. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988 Mar;139(3):461–469. doi: 10.1016/s0022-5347(17)42494-3. [DOI] [PubMed] [Google Scholar]
  13. Tannock I., Gospodarowicz M., Connolly J., Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol. 1989 Aug;142(2 Pt 1):289–292. doi: 10.1016/s0022-5347(17)38733-5. [DOI] [PubMed] [Google Scholar]
  14. Troner M., Birch R., Omura G. A., Williams S. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial. J Urol. 1987 Apr;137(4):660–662. doi: 10.1016/s0022-5347(17)44167-x. [DOI] [PubMed] [Google Scholar]
  15. Yagoda A. Chemotherapy of metastatic bladder cancer. Cancer. 1980 Apr 15;45(7 Suppl):1879–1888. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES